Structure Therapeutics Inc.
GPCR
$54.51
-$0.19-0.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 31.82% | 37.77% | 24.57% | 23.01% | 32.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.03% | 20.46% | 18.06% | 74.18% | 79.36% |
| Operating Income | -22.03% | -20.46% | -18.06% | -74.18% | -79.36% |
| Income Before Tax | -19.97% | -18.74% | -15.11% | -89.91% | -78.02% |
| Income Tax Expenses | 50.97% | 60.16% | 66.13% | 448.55% | 165.71% |
| Earnings from Continuing Operations | -20.05% | -18.85% | -15.24% | -90.58% | -78.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.05% | -18.85% | -15.24% | -90.58% | -78.17% |
| EBIT | -22.03% | -20.46% | -18.06% | -74.18% | -79.36% |
| EBITDA | -21.61% | -20.06% | -17.74% | -74.33% | -79.37% |
| EPS Basic | 0.19% | -5.79% | -7.53% | -65.16% | -39.36% |
| Normalized Basic EPS | -5.82% | -13.73% | -16.61% | -60.42% | -34.37% |
| EPS Diluted | 0.19% | -5.79% | -7.53% | -65.16% | -39.36% |
| Normalized Diluted EPS | -5.82% | -13.73% | -16.61% | -60.42% | -34.37% |
| Average Basic Shares Outstanding | 16.37% | 13.83% | 12.49% | 15.63% | 27.02% |
| Average Diluted Shares Outstanding | 16.37% | 13.83% | 12.49% | 15.63% | 27.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |